Ensayo clínico de fase 3, aleatorizado, doble ciego, de a... | EligiMed

Ensayo clínico de fase 3, aleatorizado, doble ciego, de adagrasib más pembrolizumab más quimioterapia versus placebo más pembrolizumab más quimioterapia en participantes con cáncer de pulmón de células no pequeñas no escamoso, localmente avanzado o metastásico, no tratado previamente, con mutación KRAS G12C (KRYSTAL-4).

ReclutandoFase 3ClinicalTrials.gov

ID: NCT06875310Tipo: INTERVENTIONALInicio: 24 de abr de 2025Fin estimado: 30 de abr de 2032

Resumen

Este es un ensayo clínico para evaluar la eficacia, seguridad y tolerabilidad de adagrasib más pembrolizumab más quimioterapia de doblete de platino versus placebo más pembrolizumab más quimioterapia de doblete de platino en participantes con CPNM no escamoso, localmente avanzado o metastásico, no tratado previamente, con mutación KRAS G12C.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Histologically or cytologically confirmed diagnosis of non-squamous NSCLC with evidence of KRAS G12C mutation via tumor sample and/or circulating tumor deoxyribonucleic acid (ctDNA).
Locally advanced or metastatic disease.
Measurable disease via computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria of at least 1 lesion.
No prior systemic anti-cancer therapy given for advanced or metastatic disease.
Not a candidate for definitive therapy (eg, chemoradiation or complete surgical resection).
Participants with brain metastases are eligible for enrollment, including those with untreated brain metastases. Brain metastases must be asymptomatic and not in need of immediate local therapy. Any untreated brain metastases must be ≤ 20 mm in diameter.
Any PD-L1 expression (0 to 100%) as determined by VENTANA PD-L1 (SP263) assay, Agilent PD-L1 IHC 22C3 pharmDx, or Agilent PD-L1 IHC 28-8 pharmDx.

Criterios de exclusión

Participants with an active autoimmune or inflammatory disease requiring systemic treatment within 2 years.
Uncontrolled or significant cardiovascular conditions within 6 months prior to enrollment that are ongoing or with risk of recurrence.
Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities.
Ongoing treatment with concomitant medication known to cause prolonged QTc interval and that cannot be switched to alternative treatment prior to study entry.
Treatment targeting KRAS G12C mutation (eg, sotorasib, adagrasib) in any setting.
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration.